# 🧠 Cerebrovascular Disease

## 🎯 Precision Management Revolution

The 2025 guidelines provide **refined, evidence-based protocols** for acute cerebrovascular management, distinguishing between intracerebral hemorrhage subtypes and post-endovascular therapy scenarios. These nuanced approaches optimize outcomes while minimizing harm.

### 🩸 Acute Intracerebral Hemorrhage Management

#### ⏰ Time-Critical Intervention Window

**Initiate BP control within 2 hours of symptom onset** when hematoma expansion risk peaks. This narrow window is crucial for preventing secondary injury.

Class 2a\
Selected mild-to-moderate ICH with presenting SBP 150–220: target 140 mmHg, maintain 130–150 ([AHA/ASA 2022 guideline](https://pubmed.ncbi.nlm.nih.gov/35579034/))\
Duration: 7 days post-hemorrhage

##### 💎 Critical Evidence Integration

The **refined Class 2a recommendation** reflects nuanced interpretation of INTERACT-2 (showing benefit) and ATACH-2 (showing potential harm from overly aggressive reduction). The target avoids SBP \<130 mmHg to prevent cerebral hypoperfusion in the setting of impaired autoregulation.

#### 📋 Stepwise Management Protocol

0-2 hrs

##### Initial Assessment & Stabilization

Immediate neuroimaging (CT), coagulation studies, baseline neurological assessment. Establish IV access, initiate continuous BP monitoring.

2-6 hrs

##### Intensive BP Management

**Target SBP 140 mmHg** using continuous infusion agents. Nicardipine (preferred), labetalol, or esmolol for precise titration.

6-24 hrs

##### Maintenance & Monitoring

Continue SBP 130-139 mmHg range. Serial neurological assessments, repeat imaging if deterioration. Monitor for cerebral edema.

1-7 days

##### Sustained Control

Transition to oral agents using the stroke team’s individualized target. Begin rehabilitation planning, address secondary prevention.

###### 🎯 Preferred IV Agents

- **Nicardipine:** 5-15 mg/hr infusion
- **Labetalol:** 10-20 mg boluses or 0.5-2 mg/min
- **Esmolol:** 25-300 mcg/kg/min (if no contraindications)

###### ⚠️ Avoid These Agents

- **Sublingual nifedipine:** Unpredictable, excessive reduction
- **IV hydralazine:** Uncontrolled, precipitous drops
- **IV metoprolol:** Potential CNS depression

### Post-Endovascular Therapy: Trial Evidence

#### ENCHANTED2/MT: very intensive lowering caused harm

After successful thrombectomy, ENCHANTED2/MT compared an SBP target \<120 mmHg with 140–180 mmHg for 72 hours in patients with persistently elevated BP. The \<120 strategy worsened functional outcomes. [Yang et al., Lancet 2022](https://pubmed.ncbi.nlm.nih.gov/36341753/).

Avoid the very intensive \<120 mmHg strategy tested in ENCHANTED2/MT.\
The trial does not establish that every SBP below 140 is harmful.

#### Apply the result in context

Individualize post-thrombectomy BP management with the stroke team and current local stroke protocol, accounting for reperfusion, neurologic status, hemorrhage and comorbid illness. Do not use the trial comparator as a reason to raise every lower BP to 140 mmHg. Antithrombotic decisions require a separate stroke-specific indication and bleeding assessment.

### 🧊 Acute Ischemic Stroke (Non-Endovascular)

Class 1\
Permissive hypertension: Allow SBP \<220 mmHg, DBP \<120 mmHg\
Avoid aggressive reduction in acute phase

#### 🎯 Management by Clinical Scenario

###### 💉 tPA Candidates

- Reduce SBP to \<185 mmHg before tPA
- Maintain \<180/105 mmHg for 24 hours post-tPA
- Use nicardipine or labetalol
- Monitor for hemorrhagic conversion

###### 🚫 Non-tPA Patients

- Permissive hypertension: SBP \<220 mmHg
- Avoid routine BP reduction
- Preserve penumbral perfusion
- Begin reduction after 24-48 hours

###### 🫀 Cardiac Complications

- Acute MI: standard ACS protocols
- Heart failure: careful diuresis
- Arrhythmias: rate/rhythm control
- Aortic dissection: emergency surgery

###### 🧠 Neurological Deterioration

- Cerebral edema: osmotic therapy
- Hemorrhagic conversion: BP control
- Malignant MCA syndrome: consider surgery
- Seizures: antiepileptic therapy

### 🧠 Cognitive Preservation & Dementia Prevention

#### 📈 SPRINT-MIND Evidence Integration

##### 🎯 Intensive BP Control

**19% reduction** in mild cognitive impairment with SBP \<120 mmHg vs \<140 mmHg

##### 📊 Composite Cognitive Outcomes

**15% reduction** in combined MCI and probable dementia outcomes

##### 🧪 White Matter Protection

Reduced small vessel disease progression and white matter hyperintensity burden

Class 1 Upgrade\
Target SBP \<130 mmHg for cognitive preservation\
Particularly important in midlife hypertension

##### 🔬 Mechanistic Understanding

Midlife hypertension particularly predicts late-life cognitive decline through small vessel disease, blood-brain barrier disruption, and chronic cerebral hypoperfusion. The **Class 1 upgrade** supports aggressive treatment in younger patients for brain health preservation beyond cardiovascular protection.

#### 📋 Cognitive Protection Protocol

###### 👥 Target Populations

- Adults 50+ years with CV risk factors
- No history of diabetes or stroke
- Absence of orthostatic hypotension
- Life expectancy \>3 years

###### 🎯 Implementation Strategy

- Gradual SBP reduction to \<130 mmHg
- Monitor cognitive function annually
- Screen for depression and anxiety
- Encourage cognitive stimulation

###### ⚖️ Risk-Benefit Assessment

- Balance cognitive benefits vs fall risk
- Avoid excessive reduction (\<110 mmHg)
- Consider frailty status
- Regular medication tolerance review

###### 🧪 Adjunctive Measures

- Lipid management (statins)
- Diabetes prevention/control
- Physical exercise programs
- Social engagement promotion

## 💊 Cerebrovascular-Specific Medication Considerations

| Clinical Scenario | Preferred Agents | Target BP | Monitoring | Contraindications |
|----|----|----|----|----|
| **Acute ICH** | Nicardipine, labetalol, esmolol | Selected mild-to-moderate ICH: target 140; maintain 130–150 | Continuous BP, neuro checks q1h | Sublingual nifedipine, hydralazine |
| **Post-Endovascular** | Individualized stroke-team protocol | ENCHANTED2/MT comparator: 140–180; individual clinical target varies | Neuro status, vessel patency | Very intensive target \<120 tested in ENCHANTED2/MT |
| **tPA Eligible** | Nicardipine, labetalol | SBP \<185 pre-tPA, \<180 post | BP q15min × 2hr, then q30min | Beta-blockers (relative) |
| **Chronic Prevention** | ACE inhibitors, thiazides, CCBs | SBP \<130 mmHg | Cognitive assessment annually | Excessive reduction \<110 mmHg |
| **Cognitive Preservation** | RAAS inhibitors preferred | SBP \<130 mmHg | MoCA, orthostatic vitals | Rapid titration in elderly |

## 📚 Sources

1.  **Anderson CS, Heeley E, Huang Y, et al; INTERACT2 Investigators.** Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage (INTERACT-2). *N Engl J Med.* 2013;368(25):2355-2365. [PMID: 23713578](https://pubmed.ncbi.nlm.nih.gov/23713578/). \[Source for: target SBP \<140 within 1 hour in acute ICH; primary outcome (death or major disability) numerically lower (52.0% vs 55.6%, OR 0.87, p=0.06) but did not meet significance; secondary functional outcomes favored intensive arm.\]
2.  **Qureshi AI, Palesch YY, Barsan WG, et al; ATACH-2 Investigators.** Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage (ATACH-2). *N Engl J Med.* 2016;375(11):1033-1043. [PMID: 27276234](https://pubmed.ncbi.nlm.nih.gov/27276234/). \[Source for: target SBP 110-139 vs 140-179 in acute ICH — no significant difference in primary outcome (death or disability) but more renal adverse events in intensive arm. Tempers INTERACT-2 enthusiasm.\]
3.  **PROGRESS Collaborative Group.** Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet.* 2001;358(9287):1033-1041. [PMID: 11589932](https://pubmed.ncbi.nlm.nih.gov/11589932/). \[Source for: secondary stroke prevention — perindopril+indapamide reduced stroke 28% (HR 0.72) and major vascular events 26%; foundational secondary-prevention BP-lowering evidence after stroke or TIA.\]
4.  **Anderson CS, Huang Y, Lindley RI, et al; ENCHANTED Investigators.** Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. *Lancet.* 2019;393(10174):877-888. [PMID: 30739745](https://pubmed.ncbi.nlm.nih.gov/30739745/). \[Source for: intensive BP lowering (target SBP 130-140) during/after IV thrombolysis did not improve functional outcome at 90 days but reduced symptomatic ICH (14.8% vs 18.7%, OR 0.75, p=0.0137).\]
5.  **Sandset EC, Anderson CS, Bath PM, et al; ESO Guidelines Committee.** European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. *Eur Stroke J.* 2021;6(2):XLVIII-LXXXIX. [PMID: 34780578](https://pubmed.ncbi.nlm.nih.gov/34780578/). \[Source for: ESO guideline on BP management in acute stroke — supports careful BP lowering in ICH, withholding aggressive lowering in acute ischemic stroke.\]
6.  **Whelton PK, Carey RM, Aronow WS, et al.** 2017 ACC/AHA Guideline for High Blood Pressure in Adults. *Hypertension.* 2018;71(6):e13-e115. [PMID: 29133356](https://pubmed.ncbi.nlm.nih.gov/29133356/). \[Source for: post-stroke target \<130/80 mmHg secondary prevention.\]

### 🎯 Cerebrovascular Disease: Key Learning Points

#### 🩸 Acute ICH Management

- Selected mild-to-moderate ICH: target 140 mmHg and maintain 130–150
- Avoid SBP \<130 mmHg to prevent hypoperfusion
- Use continuous infusion agents for precision
- INTERACT-2 vs ATACH-2 evidence integration

#### 🔧 Post-Endovascular Care

- ENCHANTED2/MT found harm from a target \<120 mmHg
- Individualize BP with the stroke team; the trial did not test every target below 140
- ENCHANTED-2/MT (Yang 2022) post-thrombectomy harm signal
- Gradual transition to standard targets

#### 🧠 Cognitive Preservation

- Class 1 upgrade: SBP \<130 mmHg for MCI prevention
- SPRINT-MIND: 19% reduction in cognitive impairment
- Midlife hypertension control crucial
- Balance benefits vs falls risk in elderly

📚 For Educational Purposes Only

© 2025 University of Dubuque PA Program - All Rights Reserved


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/cerebrovascular-disease-updated.html) · Markdown synchronized October 3, 2026.